Jasper Therapeutics is a clinical-stage biotechnology company with a single drug candidate, briquilimab, targeting mast cell driven diseases. Briquilimab is a monoclonal antibody that blocks the SCF/KIT signaling pathway, which mast cells depend on to survive. By blocking this pathway, briquilimab depletes mast cells from tissue rather than simply suppressing their activity — a mechanism Jasper argues is more fundamental than existing therapies like antihistamines or anti-IgE antibodies. Jasper's lead indications are Chronic Spontaneous Urticaria (CSU, hives with no identifiable trigger) and Chronic Inducible Urticaria (CIndU, hives triggered by physical stimuli), with allergic asthma as an earlier-stage opportunity. Briquilimab is in Phase 1b/2a trials across these indications, with Jasper planning a Phase 2b/3 study in CSU. Jasper licenses briquilimab exclusively from Amgen across all indications and territories. The company has no approved products and no product revenue, funding operations through equity financings. With only 22 full-time employees, Jasper's cost structure is lean, but clinical trial and manufacturing costs are substantial. If approved, Jasper intends to commercialize briquilimab directly in North America and partner outside North America, generating recurring revenue from a chronic repeat-dosing regimen — a model common to other biologic therapies in immunology and dermatology.